Antimicrobial peptide-fibrin glue mixture for treatment of methicillin-resistant Staphylococcus aureus-infected wounds

Abstract

Aim: This study was conducted to investigate the effect of fibrin glue-CM11 antibacterial peptide mixture (FG-P) on the healing of infected wounds in vivo. Materials & methods: We formulated a mixture of FG-P and evaluated its antimicrobial activity in vitro against multidrug-resistant (MDR) bacteria involved in wound infection as well as its healing effect on wound infected by methicillin-resistant S. aureus (MRSA) in vivo. Results: The peptide had an MIC of 8 μg/ml against all bacteria isolates. Growth inhibition zones were evident for FG-P compared with FG. The in vivo study showed that the FG-P could be significantly effective in healing the MRSA-infected wound. Conclusion: The use of FG-P mixture is a very suitable option for treating infected wounds.

GRAPHICAL ABSTRACT

Article highlights

• Formulation of fibrin glue (FG) with antibacterial properties that contains an antibacterial peptide for the treatment of infected wounds caused by antibiotic resistant bacteria.

• This study demonstrates in vitro antibacterial activity of the FG-P mixture against multidrug-resistant (MDR) isolates Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli and Acinetobacter baumannii bacteria commonly associated with wound infection.

• The in vivo findings showed that the FG-P could be significantly effective in healing the infected wound caused by the methicillin-resistant S. aureus.

• The peptide release assay showed that in the first 12 h, 35% of the peptide can be released from the FG and within 48 h, more than 70% are released.

• The healing process of the wound after 14 days showed that the healing is significantly better in the infected and non-infected wounds treated by FG-P mixture compared with the control groups.

Keywords: :

• antimicrobial peptide
• fibrin glue
• infection
• Staphylococcus aureus
• wound healing

Acknowledgments

We would like to thank the guidance and support from Research and Technology Comprehensive Laboratory (RTCL) of Baqiyatallah University of Medical Sciences.

Author contributions

MM Moghaddam and M Bahreini participated in study design, contributed to all experimental work, data and statistical analysis and interpretation of data reviewed the literature for the manuscript. M Ghorbani, MR Nourani and R Mirnejad contributed extensively to the interpretation of the data and the conclusion. MM Moghaddam performed final editing. All authors approved the final version of this manuscript for submission and approved the final draft.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The study was confirmed by the Ethics Committee of the Baqiyatullah University of Medical Sciences with approval ID: IR.BMSU.AEC.1401.019; and was in accordance with the ethical standards for human experimentation and the Declaration of Helsinki.